|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Pitavastatin#Adult Indications and Dosage]] |
| {{Pitavastatin}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Indications and Usage==
| |
| | |
| Drug therapy should be one component of multiple-risk-factor intervention in individuals who require modifications of their lipid profile. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and [[cholesterol]] only when the response to diet and other nonpharmacological measures has been inadequate.
| |
| | |
| ===Primary Hyperlipidemia and Mixed Dyslipidemia===
| |
| | |
| LIVALO® is indicated as an adjunctive therapy to diet to reduce elevated total [[cholesterol]] (TC), [[low-density lipoprotein]] [[cholesterol]] ([[LDL-C]]), [[apolipoprotein B]] (Apo B), [[triglyceride]]s (TG), and to increase [[HDL-C]] in adult patients with primary [[hyperlipidemia]] or mixed [[dyslipidemia]].
| |
| | |
| ===Limitations of Use===
| |
| | |
| Doses of LIVALO greater than 4 mg once daily were associated with an increased risk for severe [[myopathy]] in premarketing clinical studies. Do not exceed 4 mg once daily dosing of LIVALO.
| |
| | |
| The effect of LIVALO on cardiovascular morbidity and mortality has not been determined.
| |
| | |
| LIVALO has not been studied in Fredrickson Type I, III, and V [[dyslipidemia]]s.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = LIVALO (PITAVASTATIN CALCIUM) TABLET, FILM COATED [KOWA PHARMACEUTICALS AMERICA, INC. ] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44dcbf97-99ec-427c-ba50-207e0069d6d2 | publisher = | date = | accessdate = 14 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| {{statins}}
| |
| | |
| [[Category:Statins]]
| |
| [[Category:Quinolines]]
| |
| [[Category:Diols]]
| |
| [[Category:Carboxylic acids]]
| |
| [[Category:Organofluorides]]
| |
| [[Category:Cyclopropanes]]
| |
| [[Cardiovascular Drugs]]
| |
| [[Drugs]]
| |